Role of muscarinic receptors in the activity of N-desmethylclozapine: Reversal of hyperactivity in the phospholipase C knockout mouse

Behavioural Pharmacology

Volumn 19, Issue 5-6, 2008, Pages 543-547

  Gray, Laura ^a,c   McOmish, Caitlin ^a   Scarr, Elizabeth ^a   Dean, Brian ^a,b   Hannan, Anthony J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Locomotor activity; Mouse; Muscarinic receptors; N des methylclozapine; Phospholipase C 1 knockout

Indexed keywords

CLOZAPINE; MUSCARINIC M1 RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR; NORCLOZAPINE; PHOSPHOLIPASE C; PHOSPHOLIPASE C BETA1; PIRENZEPINE; DRUG DERIVATIVE; MUSCARINIC M1 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHOLIPASE C BETA; PLCB1 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BINDING AFFINITY; CHOLINERGIC ACTIVITY; CHOLINERGIC SYSTEM; DRUG ACTIVITY; DRUG MECHANISM; DRUG MEGADOSE; HYPERACTIVITY; KNOCKOUT MOUSE; LOCOMOTION; LOW DRUG DOSE; MOUSE; NONHUMAN; PSYCHOSIS; RECEPTOR INTRINSIC ACTIVITY; ANIMAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; GENETICS; GENOTYPE; MOTOR ACTIVITY; MOUSE MUTANT; PHENOTYPE;

ANIMALS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENOTYPE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; MUSCARINIC ANTAGONISTS; PHENOTYPE; PHOSPHOLIPASE C BETA; PIRENZEPINE; RECEPTOR, MUSCARINIC M1;

EID: 58149354892     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32830c3669     Document Type: Article

References (25)

1. Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calligaro DO, McKinzie DL (2003a). Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1125-1143.
2. Bymaster FP, McKinzie DL, Felder CC, Wess J (2003b). Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res 28:437-442.
3. Chintoh A, Fulton J, Koziel N, Aziz M, Sud M, Yeomans JS (2003). Role of cholinergic receptors in locomotion induced by scopolamine and oxotremorine-M. Pharmacol Biochem Behav 76:53-61.
4. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL (2005). The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology (Berl) 178:451-460.
5. Frazier JA, Cohen LG, Jacobsen L, Grothe D, Flood J, Baldessarini RJ, et al. (2003). Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. J Clin Psychopharmacol 23:87-91.
6. Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S (2001). Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci U S A 98:15312-15317.
7. Gray JA, Roth BL (2001). Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 56:441-451.
8. Hannan AJ, Kind PC, Blakemore C (1998). Phospholipase C-beta1 expression correlates with neuronal differentiation and synaptic plasticity in rat somatosensory cortex. Neuropharmacology 37:593-605.
9. Hannan AJ, Blakemore C, Katsnelson A, Vitalis T, Huber KM, Bear M, et al. (2001). PLC-beta1, activated via mGluRs, mediates activity-dependent differentiation in cerebral cortex. Nat Neurosci 4:282-288.
10. Katner SN, McBride WJ, Lumeng L, Li TK, Murphy JM (1996). Effects of cholinergic agents on locomotor activity of P and NP rats. Alcohol Clin Exp Res 20:1004-1010.
11. Kim D, Jun KS, Lee SB, Kang NG, Min DS, Kim YH, et al. (1997). Phospholipase C isozymes selectively couple to specific neurotransmitter receptors. Nature 389:290-293.
12. Kind PC, Kelly GM, Fryer HJ, Blakemore C, Hockfield S (1997). Phospholipase C-beta1 is present in the botrysome, an intermediate compartment-like organelle, and Is regulated by visual experience in cat visual cortex. J Neurosci 17:1471-1480.00 Lameh J, Burstein ES, Taylor E, Weiner DM, Vanover KE, Bonhaus DW (2007). Pharmacology of N- desmethylclozapine. Pharmacol Ther 115:223-231.
13. Manschreck TC, Boshes RA (2007). The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry 15:245-258.
14. Mathur A, Shandarin A, LaViolette SR, Parker J, Yeomans JS (1997). Locomotion and stereotypy induced by scopolamine: contributions of muscarinic receptors near the pedunculopontine tegmental nucleus. Brain Res 775:144-155.
15. Mauri MC, Volonteri LS, Dell'Osso B, Regispani F, Papa P, Baldi M, Bareggi SR (2003). Predictors of clinical outcome in schizophrenic patients responding to clozapine. J Clin Psychopharmacol 23:660-664.
16. McOmish CE, Burrows E, Howard M, Scarr E, Kim D, Shin HS, et al. (2007). Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration. Mol Psychiatry 13:661-672.
17. Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S (2007). Evaluation of N-desmethylclozapine as a potential antipsychotic - preclinical studies. Neuropsychopharmacology 32:1540-1549.
18. Shapovalova KB, Kamkina YV, Mysovskii DA (2005). The effects of microinjection of the selective blocker of muscarinic M1 receptors pirenzepine into the neostriatum on the motor behavior of rats. Neurosci Behav Physiol 35: 589-594.
19. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, et al. (2006). Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 63:721-730.
20. Spires TL, Molnar Z, Kind PC, Cordery PM, Upton AL, Blakemore C, Hannan AJ (2005). Activity-dependent regulation of synapse and dendritic spine morphology in developing barrel cortex requires phospholipase C-beta1 signalling. Cereb Cortex 15:385-393.
21. Sporn AL, Vermani A, Greenstein DK, Bobb AJ, Spencer EP, Clasen LS, et al. (2007). Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 46:1349-1356.
22. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, et al. (2003). N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity. Proc Natl Acad Sci U S A 100:13674-13679.
23. Tandon R (2002). Safety and tolerability: how do newer generation 'atypical antipsychotics compare? Psychiatr Q 73:297-311.
24. Ukai M, Shinkai N, Kameyama T (1995). Cholinergic receptor agonists inhibit pirenzepine-induced dysfunction of spontaneous alternation performance in the mouse. Gen Pharmacol 26:1529-1532.
25. Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, et al. (2004). The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl) 177:207-216.